Sabadell - Airbus Group SE (AIR) ... EUROSTOXX 50: RESULTADOS A DESTACAR SEMANA 28 OCTUBRE A 1 NOVIEMBRE 2019 (ANÃLISIS BANCO SABADELL)

Report

Sabadell

Research Department

EUR 100.00 For Business Accounts Only

EUROSTOXX 50: RESULTADOS A DESTACAR SEMANA 28 OCTUBRE A 1 NOVIEMBRE 2019 (ANÃLISIS BANCO SABADELL)

Resultados Euro Stoxx 50 3Tâ€™19 destacados la prÃ³xima semana.
De los valores que publican Rdos. 3Tâ€™19 la semana que viene del EuroStoxx50 (ver fechas en calendario en este informe) esperamos impacto positivo en: (i) Sanofi por la evoluciÃ³n de Pharma que deberÃa permitir recuperar parte del terreno perdido en cotizaciÃ³n. Por el lado negativo destacamos: i) Airbus, cuyos Rdos. se verÃ¡n presionados por el menor ritmo de entregas de AviaciÃ³n Comercial e ii) ING, donde seguimos viendo debilidad en Rdos. y que ha tenido un buen performance reciente.

23/10/2019 7 ES

Underlyings

Airbus Group SE

See profile

US0092791005 Germany

ING Groep NV

See profile

Sanofi

Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.

See profile

FR0000120578 Euronext Paris France

Provider

Sabadell

See profile

Analysts

Research Department

Other Reports on these Companies

GlobeNewsWire

Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty

Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty Paris, May 13, 2024. As the largest private contributor to the security and independence of France's health ecosystem, Sanofi today announces an investment of more than €1 billion to create new bioproduction capacity at its sites in Vitry-sur-Seine (Val de Marne), Le Trait (Seine-Maritime) a...

May 13, 2024 May 13, 2024 1 EN

GlobeNewsWire

Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Accelerates potential for development of a novel flu-COVID-19 combination product based on authorized vaccines with ...

May 10, 2024 May 10, 2024 1 EN

GlobeNewsWire

Communiqué de presse : Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19

Communiqué de presse : Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19 Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19 L’accord, qui combinera la puissance commerciale des deux entreprises, permettra aux patients de bénéficier à partir de 2025 d’un meilleur accès à un vaccin adjuvanté à base de protéines, non-ARNm, contre la COVID-19 Accélération du ...

May 10, 2024 May 10, 2024 1 EN

COLONIAL: MÁS DETALLES SOBRE LA ENTRADA DE CRITERIA EN EL CAPITAL DE COLONIAL (ANÁLISIS BANCO SABADELL)

COL ha anunciado un acuerdo con Criteria por el cual ésta se ha comprometido a suscribir acciones nuevas de COL por un importe de 622 M euros (c.16,78% del capital, subiría su participación a c.20%) a un precio de 7,1 euros/acc. (+15% sobre cierre previo, con descuento del -29% sobre NTA’23 y con descuento del -2,5% frente a nuestro P.O.).

EUR 50.00

May 17, 2024 May 17, 2024 1 ES

Ignacio Romero

Ignacio Romero

MERLIN PROPERTIES: RDOS. 1T’24 (ANÁLISIS BANCO SABADELL)

Rdos. 1T'24 vs 1T'23: Ingresos brutos por rentas: 124,2 M euros (+4,2% vs +0,9% BS(e)); EBITDA: 91,0 M euros (+0,7% vs -1,2% BS(e)).

EUR 100.00

May 17, 2024 May 17, 2024 1 ES

Research Department

Research Department

IBERIAN DAILY 17 MAY (ANÁLISIS BANCO SABADELL)

NEWS SUMMARY: BANKING SECTOR, CELLNEX, COLONIAL, FCC, GRIFOLS, MERLIN PROPERTIES, OHLA. European stock markets pause for a break European stock markets saw moderate corrections after several sessions of gains that led the Stoxx 600 to record highs and the Ibex to 2015 highs above 11,300 pints. In the STOXX 600, Insurance and Basic Resources were the best performers vs. the losses of Autos and industrials. On the macro side, in the US, April’s industrial output stagnated, contrary to expectations, May’s Philadelphia Fed index dropped more than expected and April’s housing starts climbed less ...

EUR 100.00

May 17, 2024 May 17, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

EUROSTOXX 50: RESULTADOS A DESTACAR SEMANA 28 OCTUBRE A 1 NOVIEMBRE 2019 (ANÃLISIS BANCO SABADELL)

Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty

Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

Communiqué de presse : Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19

COLONIAL: MÁS DETALLES SOBRE LA ENTRADA DE CRITERIA EN EL CAPITAL DE COLONIAL (ANÁLISIS BANCO SABADELL)

MERLIN PROPERTIES: RDOS. 1T’24 (ANÁLISIS BANCO SABADELL)

IBERIAN DAILY 17 MAY (ANÁLISIS BANCO SABADELL)

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe

EUROSTOXX 50: RESULTADOS A DESTACAR SEMANA 28 OCTUBRE A 1 NOVIEMBRE 2019 (ANÃLISIS BANCO SABADELL)